NCT04000594View on ClinicalTrials.gov

A Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 (RG6042) in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 2, 2019

Primary Completion Date

January 18, 2022

Study Completion Date

January 18, 2022

Conditions
Huntingtons Disease
Interventions
DRUG

RO7234292 (RG6042)

RO7234292 (RG6042) will be administered in two IT doses of the same dose level at an interval of 28 days during the treatment period (Day 1 and Day 29). Each dose of RO7234292 (RG6042) will be administered as a single IT bolus injection.

Trial Locations (3)

2333

Centre For Human Drug Research; Research, Leiden

WC1N 3BG

Leonard Wolfson Experimental Neurology Centre, London

M13 9WL

Manchester University NHS Foundation Trust (MFT), Manchester

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT04000594 - A Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 (RG6042) in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington's Disease | Biotech Hunter | Biotech Hunter